Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis
Ultra-sound Guided Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Joint Osteoarthritis
Knee osteoarthritis, as a progressive disease is one of the most common causes of pain, motor disorder and disability in the elderly. By increasing age, the cartilage is eroded and endures degenerative changes due to physiological and biomechanical changes as well as metabolic effects and trauma . Non-surgical interventions for pain control of knee osteoarthritis include weight loss, exercise, changes in daily activities, physiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics .However ,the intra-articular injection is recently recommended by many studies such as corticosteroids, hyaluronic acid, Growth hormone, dextrose ,and platelet rich plasma.
Intra-articular injection of platelets are activated and undergo degranulation, releasing a range of growth factors, including transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor, vascular endothelial growth factors, epidermal growth factors and basic fibroblast growth factor 2. These growth factors are thought to activate a variety of signaling pathways, which promote healing of bone and soft tissue.Also,some minimally invasive therapeutic options have been effective in pain relieve in KA, such as ultrasound-guided saphenous nerve block .
調査の概要
状態
詳細な説明
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
DK
-
Mansourah、DK、エジプト、050
- Mansoura University Hospitals
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients who are not competent to understand the study protocol
- Radiographic evidence of OA of knee of 2nd degree.
- Chronic pain for at least 6 months prior to study entry (day 0).
- Pain relief not achieved with conservative therapies during the last 6 months
Exclusion Criteria:
- Patient refusal.
- Bleeding disorders.
- Coagulation disorders.
- Local skin infection
- Current other problem in the affected extremity .
- Psychiatric disorders affecting co-operation of the patient .
- Previous chronic opioid use.
- Intra articular knee injection within previous three months.
- History of traumatic arthropathy.
- History of neuropathic arthropathy.
- Allergy or hypersensitivity to any of the study medication.
- Any condition that could interfere with the interpretation of the outcome assessments.
- Pregnancy
- Lactating women.
- low back pain due to central cause.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Saphenous nerve block group
Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
|
Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
|
|
実験的：Platelet rich plasma group
Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
|
Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain scores
時間枠：For 6 months after intervention
|
The severity of pain will be assessed using a visual analog scale (VAS)
|
For 6 months after intervention
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of life (QOL)
時間枠：For 6 months after intervention
|
is evaluated using the Western Ontario and MC Master universities (WOMAC) index of osteoarthritis
|
For 6 months after intervention
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。